Travere Therapeutics, Inc. (TVTX)

AI-Powered SEC Filing Analysis

Current Report Filed: 2026-04-14

Key Insights

The FDA has approved Travere Therapeutics' FILSPARI (sparsentan) for the treatment of focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome, marking the first FDA-approved therapy for this condition.
In the Phase 3 DUPLEX study, FILSPARI demonstrated statistically significant improvements in proteinuria reduction and eGFR preservation compared to the control treatment in patients with FSGS without nephrotic syndrome.
The addressable patient population for FILSPARI in FSGS without nephrotic syndrome is estimated to be over 30,000 individuals in the U.S., representing a significant commercial opportunity for the company.

Insider Trading Filed: 2026-04-07

Key Insights

The reporting person, Roy D. Baynes, exercised 10,000 stock options at $26.52 and subsequently sold 10,000 shares at $33, indicating insider selling activity.
The sale was made pursuant to a pre-arranged 10b5-1 trading plan, suggesting the transaction was part of a planned strategy rather than opportunistic trading.
The reporting person still holds 37,500 shares of Travere Therapeutics, Inc. (TVTX) after the reported transaction, indicating he maintains a significant ownership stake in the company.

Insider Trading Filed: 2026-01-21

Key Insights

The reporting person, Elizabeth E. Reed, who is the Chief Legal Officer and General Counsel of Travere Therapeutics, Inc., exercised 10,000 employee stock options and immediately sold the same number of shares at a weighted average price of $27.3420 per share.
The stock option exercise and sale were made pursuant to a pre-existing written plan that meets the requirements of Rule 10b5-1(c) of the Securities Exchange Act, indicating a planned transaction rather than an opportunistic trade.
Following the transaction, the reporting person still holds 90,270 shares of Travere Therapeutics' common stock, indicating a continued ownership interest in the company.

Current Report Filed: 2026-01-13

Key Insights

The FDA has extended the review timeline for Travere Therapeutics' supplemental New Drug Application (sNDA) for FILSPARI® (sparsentan) in focal segmental glomerulosclerosis (FSGS), with a new Prescription Drug User Fee Act (PDUFA) target action date of April 13, 2026.
If approved, FILSPARI would be the first medication indicated for FSGS, a rare and serious kidney disorder that can lead to progressive kidney function loss and kidney failure.
The extension follows the recent submission of responses requested by the FDA to further characterize the clinical benefit of FILSPARI, and no additional information relating to the safety or manufacturing of FILSPARI has been requested.

Get real-time filing analysis in the app

Download on the App Store

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.